A comparison of visual problems in the Parkinsonian syndromes
Abstract
Five disorders currently comprise the ‘Parkinsonian syndromes’, viz. Parkinson’s disease (PD), progressive supranuclear palsy (PSP), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and corticobasal degeneration (CBD). Differential diagnosis of these disorders can be challenging but if ocular signs and symptoms are present they may aid clinical diagnosis. Visual problems in the Parkinsonism syndromes may involve visual acuity (VA), contrast sensitivity (CS), color vision, pupil reactivity, and eye movements; more complex aspects of vision such as reading ability, visuo-spatial orientation, the identification and naming of objects, and visual hallucinations. No single visual feature can definitively diagnose a specific Parkinsonism syndrome. Nevertheless, the presence of visual hallucinations and color vision problems may be more characteristic of DLB and PD than CBD or PSP and vertical supranuclear gaze palsy may be a significant feature of PSP. In addition, variation in saccadic eye movement (SEM) problems may help to distinguish PD and CBD from PSP. A multidisciplinary approach is often necessary to manage the visual problems of patients with a Parkinsonism syndrome.
Keywords
Full Text:
Subscribers OnlyReferences
Armstrong RA. Visual signs and symptoms of Parkinson’s disease. Clin Exp Optom 2008; 91 (2): 129-138. DOI:10.111/j.1444-0938.2007.0021.x
Armstrong RA. Visual signs and symptoms of dementia with Lewy bodies. Clin Exp Optom 2012; 95 (6): 621-630. DOI:10.1111/j.1444-0938.2012.00770.x
Armstrong RA. Visual signs and symptoms of progressive supranuclear palsy. Clin Exp Optom 2011; 95 (2): 150-160. DOI:10.1111/j.1444-0938.2010.00504.x
Armstrong RA. Visual signs and symptoms of multiple system atrophy. Clin Exp Optom 2014; 97 (6): 483-491. DOI:10.1111/cxo.12206
Armstrong RA. Visual signs and symptoms of corticobasal degeneration. Clin Exp Optom 2016; 99 (6): 498-506. DOI:10.1111/cxo.12429
Antal A, Bandini P, Keri S, Bodis-Wollner I. Visuo cognitive dysfunctions in Parkinson’s disease. Clin Neurosci 1998; 5 (2):147-152.
Armstrong RA. Oculo-visual dysfunction in Parkinson’s disease. J Park Dis 2015; 5 (4): 715-726. DOI:10.3233/JPD-150686
Earley CJ. Restless legs syndrome. New Eng J Med 2003; 348 (21), 2103-2109. DOI:10.1056/NEJMcp021288
Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology 2001, 57 (8), 1497-1499.
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson disease: a clinic-pathological study of 100 cases. J Neurol Neurosurg Psy 1992 (3); 55: 181-184. DOI:10.1136/jnnp.55.3.181
McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardosn JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen ENH, Ballard C, de Vos RAI, Wilcock GK, Jellinger KA, Perry RH. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996; 47 (5): 1113-1124.
Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Davoisen RC, Goetz CG, Golbe LI, Grafman J, Growden JH, Hallett M, Jankovic J, Quinn NP, Tolisa E, Zee DS, Chase TW, FitzGibbon EJ, Hall Z, Juncos J, Nelson KB, Oliver E, Pramstaller P, Reich SG, Verny M. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop. Neurology 1996a; 47: 1-9.
Litvan I, Hauw JJ, Bartko JJ, Lantos PL, Daniel SE, Horoupian DS, McKee A, Dickson D, Bancher C, Tabaton M, Jellinger K, Anderson DW. Validity and reliability of the preliminary NINDS neuropathological criteria for progressive supranuclear palsy and related disorders. J Neuropath Exp Neurol 1996b; 55 (1): 97-105.DOI:10.1097/00005072-196601000-00010
Gilman S, Wenning GJK, Low PA, Brooks DJ, Mattias CJ, Trojanowski JQ, Wood NW, Colosima C, Durr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poese W, Quinn N, Revesz T, Robertson D, Sandroni T, Seppi K, Vidailhet M. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71 (9): 670-676. DOI:10.1212/01.wnl.0000324625.00404.15
Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K, Jellinger K, Lantos PL, Lippa CF, Mirra SS, Tabaton M, Vonsattel JP, Wakabayashi K, Litvan I. Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropath Exp Neurol 2002; 61 (11): 935-946. DOI:10.1093/jnen/61.11.935
Sagar H. Parkinson's disease. Optima Health Guides. Macdonald & Co., London, 1991.
Walton J. Brain's Diseases of the Nervous System. pp 322-336, Oxford University Press, Oxford, 1985.
Wu T, Wang J, Wang CD, Hallett M, Zang YF, Wu XL, Chan P. Basal ganglia circuits changes in Parkinson’s disease. Neurosci Lett 2012; 524 (1): 55-59. DOI:10.1016/j.neulet.2012.07.012
Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neurosci Lett 1998; 251 (3): 205-208.
Kovacs GG, Milenkovic IJ, Preusser M, Budka H. Nigral burden of alpha-synuclein correlates with striatal dopamine deficit. Move Disord 2008; 23 (11): 1608-1612. DOI:10.1002/mds.22207
Lippa CF, Smith TW, Swearer JM. Alzheimer’s disease and Lewy body disease: A comparative clinicopathological study. Ann Neurol 1994; 35 (1): 81-88. DOI:10.1002/ana.410350113
Galasko D, Katzman R, Salmon DP, Hansen I. Clinical and neuropathological findings in Lewy body dementias. Brain Cog 1996; 31(2): 166-175. DOI:10.1006/brcg.1996.0040
Cummings JL. Dementia with Lewy bodies: Molecular pathogenesis and implications for classification. J Geriatr Psychol Neurol 2004; 17 (3): 112-119. DOI:10.1177/0891988704267473
Mann DMA, Snowden JS. The topographic distribution of brain atrophy in cortical Lewy body Disease: comparison with Alzheimer’s disease. Acta Neuropathol 1995; 89 (2): 178-183.
Robles A, Cacabelos P. Dementia with Lewy Bodies: New data for the understanding of neuroimaging. Rev Neurol 1999; 29 (11): 993-998.
Jellinger KA, Attems J. Does striatal pathology distinguish Parkinson’s disease with dementia from dementia with Lewy bodies? Acta Neuropathol 2006; 112 (3): 253-260. DOI:10.1007/s00401-006-0088-2
Perneczky R, Haussermann P, Diehl-Schmid J, Boecker H, Forstl H, Drzezga A, Kurz A. Metabolic correlates of brain reserve power in dementia with Lewy bodies: An FDG PET study. Dem Geriatr Cog Disord 2007; 23 (6): 416-422. DOI:10.1159/000101956
Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125 (2): 391-403. DOI:10.1093/brain/awf033
Steele JC, Richardson JC, Olszewski T. Progressive supranuclear palsy. Arch Neurol 1964; 10: 333-359.
Papapetropoulos S, Gonzalez J, Mash DC. Natural history of progressive supranuclear palsy: a clinicopathologic study from a population of brain donors. Eur Neurol 2005; 54 (1): 1-9. DOI:10.1159/000086754
Gomez-Haro C, Espert-Tortajada R, Gadea-Domenech M, Navarro-Humanes JF. Progressive supranuclear palsy: Neurological, neuropathological and neuropsychological aspects. Revis Neurol 1999; 29 (10): 936-956.
Saini J, Bagepally BS, Sandhya M, Pasha SA, Yadav R, Thennarasu K, Pal PK. Subcortical structures in progressive supranuclear palsy: vertex-based analysis. Eur J Neurol 2013; 20 (3): 493-501. DOI:10.1111/j.1468-1331.2012.03884.x
Cordato NJ, Halliday GM, Harding AJ, Hely MA, Morris JGL. Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. Ann Neurol 2000; 47 (6): 718-728. DOI:10.1002/1531-8249(200006)47:6<718::AID.ANA4>3.0.CO;2-J
Armstrong RA, Lantos PL, Cairns NJ. Progressive supranuclear palsy (PSP): a quantitative study of the pathological changes in cortical and subcortical areas of eight cases. J Neural Transm 2007; 114 (12): 1569-1577. DOI:10.1007/s00702-007-0796-3
Conrad C, Andreadis A, Trojanwski JQ, Dickson DW, Kang D, Chen XH, Wiederholt W, Hansen L, Masliah E, Thal LJ, Katzman R, Xia Y, Saitoh T. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol 1997; 41 (2): 277-281.DOI:10.1002/ana.410410222
Probst-Cousin S, Kayser C, Heuss D, Neundorfer B. Thirty years of multiple system atrophy concept: Review and survey of multiple system atrophy. Fortschritte Neurol Psych 2000; 68 (1): 25-36. DOI:10.1055/s-2000-11790
Wenning GK, Tison F, Ben-Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Move Disord 1997; 12 (2): 133-147. DOI:10.1002/mds.870120203
Horimoto Y, Aiba I, Yasuda T, Ohkawa Y, Katayama T, Yokokawa Y, Goto A, Ito Y. Cerebral atrophy in multiple system atrophy by MRI. J Neurol Sci 2000; 173 (2): 109-112. DOI:10.1016/S0022-510X(99)00308-1
Konagaya M, Sakai M, Matsuoka Y. Konagaya Y, Hashizume Y. Multiple system atrophy with remarkable frontal lobe atrophy. Acta Neuropathol 1999; 97 (4): 423-428.
Tsuchiya K, Watabiki S, Sano M, Iobe H, Shiotsu H, Taki K, Hashimoto K. Distribution of cerebellar cortical lesions in multiple system atrophy: a topographic neuropathological study of three autopsy cases in Japan. J Neurol Sci 1998; 155 (4): 80-85. DOI:10.1016/S0022-510X(97)00279-7
Lantos PL. Cellular pathology of multiple system atrophy: a review. J Neurol Neurosurg Psy 1994; 57 (2): 129-13. DOI:10.1136/jnnp.57.2.129
Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy, and Shy-Drager syndrome). J Neurol Sci 1989; 94 (1-3): 79-100. DOI:10.1016/0022-510X(89)90219-0
Dickson DW, Liu WL, Liu WK, Yen SH. Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol 1999; 9 (4): 721-732.
Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration: a clinical study of 36 cases. Brain 1994; 117 (5): 1183-1196. DOI:10.1093/brain/117.5.1183
Schneider JA, Watts RL, Gearing M, Brewer RP, Mirra SS. Corticobasal degeneration: Neuropathological and clinical heterogeneity. Neurology 1997; 48 (4): 959-969.
Ueno E. Clinical features of corticobasal degeneration. Neuropathology 1996; 16 (4): 253-256. DOI:10.1111/j.1440-1789.1996.tb00190.x
Wadia PM, Lang AE. The many faces of corticobasal degeneration. Park Dis Rel Disord 2007; 13 (3): S336 – S340. DOI:10.1016/S1353-8020(08)70027-0
Wenning GK, Litvan I, Jankovic J, Granata R, Mangone CA, McKee A, Poewe W, Jellinger K, Chandhuri KR, D’Olhaberriague L, Pearce RKB. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol, Neurosurg Psych 1998; 64 (2): 184-189. DOI:10.1136/jnnp.64.2.184
Tsuchiya K, Ikeda K, Uchihara T, Oda T, Shimada H. Distribution of cerebral cortical lesions in corticobasal degeneration: a clinicopathological study of five autopsy cases in Japan. Acta Neuropathol 1997; 94 (5): 416-424. DOI:10.1007/s004010050728
Ikeda K. Basic pathology of corticobasal degeneration. Neuropathology 1997; 17 (2): 127-133. DOI:10.1111/j.1440-1789.tb00026x
Markus HS, Lees AJ, Lennox G, Marsden CD, Costa DC. Patterns of regional cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT: Comparison with Parkinson's disease and normal controls. Movement Disorders 1995; 10 (2): 179-187. DOI:10.1002/mds.870100208
Kawasaki K, Iwanaga K, Wakabayashi K, Yamada M, Nagai H, Idezuka J, Homna Y, Ikuta F. Corticobasal degeneration with neither argyrophilic inclusions nor tau abnormalities: a new subgroup. Acta Neuropathol 1996; 91 (2): 140-144.
Rippon GA, Staugaitis SM, Chin SSM, Goldman JE, Marder K. Corticobasal syndrome with novel argyrophilic glial inclusions. Movement Disorders 2005; 20 (5): 598-602. DOI:10.1002/mds.20396
Mori H, Oda M. Ballooned neurons in corticobasal degeneration and progressive supranuclear palsy. Neuropathology 1997; 7 (3): 248-252. DOI:10.1111/j.1440-1789.1997.tb00047.x
Komori T, Arai N, Oda M, Nakayama H, Murayama S, Amano N, Shibata N, Kobayashi M, Sasaki S, Yagishita S. Morphologic differences in neuropil threads in Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy: a morphometric study. Neurosci Lett 1997; 233 (2-3): 89-92. DOI:10.1016/S0304-3940(97)00635-6
Matsumoto S, Udaka F, Kameyama M, Kusaka H, Ito H, Imai T. Subcortical neurofibrillary tangles, neuropil threads and argentophilic glial inclusions in corticobasal degeneration. Clin Neuropathol 1996; 15 (4): 209-214.
Dickson DW, Feany MB, Yen SH, Mattiace LA, Davies P. Cytoskeletal pathology in non-Alzheimer degenerative dementia: new lesions in diffuse Lewy body disease, Pick's disease and corticobasal degeneration. J Neural Transm 1996; 47: 31-46.
Armstrong RA, Kergoat H. Oculo-visual changes and clinical considerations affecting older patients with dementia. Ophthal Physioll Opt 2015; 35 (4): 352-376. DOI:10.10.1111/opo.12220
Metzler-Baddeley C, Baddeley RJ, Lovell PG, Laffan A & Jones RW. Visual impairment in dementia with Lewy bodies and posterior cortical atrophy. Neuropsychology 2010; 24 (1): 35-48. DOI:10.137/a0016834
Repka MX, Claro MC, Loupe DN & Reich SG. Ocular motility in Parkinson's disease. J Pediat Ophth Strab 1996; 33 (3): 144-147.
Jones RD & Donaldson IM. Fractionation of visuo-perceptual dysfunction in Parkinson's disease. J Neurol Sci 1995; 131 (1): 43-50. DOI:10.1016/0022-510X(95)00043-2
Jones RD, Donaldson IM, Timmings PL. Impairment of high-contrast visual activity in Parkinson's disease. Move Disord 1992; 7 (3): 232-238. DOI:10.1002/mds.870070308
Matsui H, Udaka F, Tamura A, Oda M, Kubori T, Nishinaka K, Kameyama M. Impaired visual acuity as a risk factor for visual hallucinations in Parkinsons’s disease. J Geriatr Psych Neurol 2006; 19 (1): 36-40. DOI:10.1177/0891988705284739
Rajagopal R, Bateman R, Van Stavern GP. Visual involvement in corticobasal syndrome. J Neuro-ophthalmol 2012; 32 (4): 338-340. DOI:10.1097/WNO.Ob013e3182305162
Price MJ, Feldman RG, Adelberg D & Kayne H. Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology 1992; 42 (4): 887-890.
Buttner T, Kuhn W, Klotz P, Steinberg R, Voss L, Bulgaru U, Przuntek H. Disturbance of color perception in Parkinson's disease. J Neural Transm 1993 (1); 6: 11-15. DOI:10.1007/BF02252618
Diederich NJ, Raman R, Leurgans S, Goetz CG. Progressive worsening of spatial and chromatic processing deficits in Parkinson’s disease. Arch Neurol 2002; 59 (8): 1249-1252. DOI:10.001/archneur.59.8.1249
Vesela O, Ruzicka E, Jech R, Roth J, Stepankova K, Mecir P, Solano Z, Preclikova E. Color discrimination is not a reliable early marker of Parkinson’s disease. J Neurol 2001; 248 (11): 975-978. DOI:10.1007/s004150170051
Postuma RB, Gagnon JF, Vendette M, Desjardins C & Montplaisir JY. Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep disorder. Ann Neurol 2011; 69 (5): 811-818. DOI:10.1002/ana.22282
Cronin-Golomb A, Corkin S, Rizzo JF, Cohen J, Growden JH, Banks KS. Visual dysfunction in Alzheimer's disease: relation to normal ageing. Ann Neurol 1991; 29 (1): 41-52. DOI:10.1002/ana410290110
Kiyosawa M, Bosley TM, Chawluk J, Jamieson D, Schatz NJ, Savino PJ, sergott RC, Reivich M, Alavi A. Alzheimer's disease with prominent visual symptoms; clinical and metabolic evaluation. Ophthalmology 1989; 96 (7): 1077-1085.
Sun L, Zhang H, Gu ZQ, Cao M, Li DW & Chan P. Stereopsis impairment is associated with decreased color perception and worse motor performance in Parkinson’s disease. Eur J Med Res 2014; Article number 19.
Bulens C, Meerwaldt JD, Van der Wildt GJ & Van Deursen JBP. Effect of levodopa treatment on contrast sensitivity in Parkinson's disease. Ann Neurol 1987 (3); 22: 365-369. DOI:10.1002/ana.41022031(3)
Hutton JT, Morris JL & Elias JW. Levodopa improves spatial contrast sensitivity in Parkinson's disease. Arch Neurol 1993; 50 (7), 721-724.
Rodnitzky RL. Visual dysfunction in Parkinson’s disease. Clin Neurosci 1998 (2); 5: 102-106.
Buttner T, Muller T & Kuhn W. Effects of apomorphine on visual functions in Parkinson’s disease. J Neural Transm 2000; 107 (1): 87-94. DOI:10.1007/s007020050007
Rascol O, Sabatini U, Fabre N, Senard JM, Simonett-Amoreau M, Montastruc JL Clanet M, Rascol A. Abnormal vestibulo-ocular cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson’s disease. Movement Disorders 1995; 10 (2): 163-170. DOI:10.1002/mds.870100206
Ture S, Inci I, Gedizlioglu M. Abnormalities of contrast sensitivity, visual fields and visual evoked potentials in Parkinson’s disease and effect of dopaminergic treatment. J Neurol 2007; 254 (3): 93-93.
Bayer AU, Keller ON, Ferrari F, Maag KP. Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer’s disease and Parkinson’s disease. Am J Ophthalmol 2002; 133 (1): 135-137. DOI:10.1016/S0002-9394(01)01196-5
Biousse V, Newman NJ, Carroll C, Mewes K, Vitek JL, Bakay RAE. et al. Visual fields in patients with posterior GPi pallidotomy. Neurology 1998; 50 (1): 258-265. DOI:10.1212/WNL.50.1.258
Bashir K, Elbe RJ, Ghabrial M, Struble RG. Hemianopsia in dementia with Lewy bodies. Arch Neurol 1998; 55(8): 1132-1135. DOI:10.1001/archneur.55.8.1132
Lobotesis K, Fenwick JD, Phipps A, Tyman A, Swann A, Ballard C, McKeith IG, O’Brien JT. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not Alzheimer’s disease. Neurology 2001; 56 (5): 643-649.
Barnes CS, Yan J, Wilmot GR. A negative electroretinogram (ERG) in a case of probable multiple system atrophy (MSA). Doc Ophthalmol 2009; 118 (3): 247-256. DOI:10.1007/s10633-0088-9156-3
Grandas F, Esteban A. Eyelid motor abnormalities in progressive supranuclear palsy. J Neurol Transm (Supp) 1994; 42: 33-41.
Valls-Sole J, Valldeoriola F, Tolosa E, Marti MJ. Distinctive abnormalities of facial reflexes in patients with progressive supranuclear palsy. Brain 1997; 120 (10): 1877-1883. DOI:10.1093/brain/120.10.1877
Piccione F, Mancini E, Tonin P, Bizzarini M. Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: report of two cases. Arch Phys Med Rehab 1997; 78 (5): 525-529. DOI:10.1016/S0003-9993(97)90169-6
Biousse V, Skibell BC, Watts RL, Loupe DN, Drews-Botsch C, Newman, NJ. Ophthalmologic features of Parkinson’s disease. Neurology 2004; 62 (2): 177-180.
Peshori KR, Schicatano EJ, Gopalaswamy R, Sahay E, Evinger C. Aging of the trigeminal blink system. Exp Brain Res 2001; 136 (3): 351-363. DOI:10.1007/s002210000585
Bonanni L, Anzelloti F, Varanese S, Thomas A, Manzoli L, Onofrj M. Delayed blink reflex in dementia with Lewy bodies. J Neurol Neurosurg Psychiatr 2007; 78 (10): 1137-1139. DOI: 10.1136/jnnp.2006.113746
Anzellotti F, Bonanni L, Iorio E, Di Baldassarre F, D’Andreagiovanni A, Monaco D, Thomas A, Onofrj M. Delayed blink reflex in dementia with Lewy bodies is sensitive to cholinergic stimulation. Clin Neuropharmacol 2008; 31 (4): 231-237. DOI:10.1097/WNF.OBO13E31815E5D7F
Kagohashi M, Okuma Y, Fujishima K, Kitada Y, Mizuno Y. Blepharospasm associated with multiple system atrophy: a case report and review of the literature. Parkin Rel Disord 2004; 10 (3): 169-171. DOI:10.1016/j.parkreldis.2003.12.002
Sepe-Monti M, Giubilei F, Marchione F, Colosimo C. Apraxia of eyelid opening in a case of atypical corticobasal degeneration. J Neural Transm 2003; 110 (10): 1145-1148. DOI:10.1007/S00702-003-0032-8
Tolosa E, Compta Y. Early and prominent blepharospasm in untreated patients with Parkinsonism should raise suspicion of progressive supranuclear palsy, multiple system atrophy, or corticobasal degeneration. J Neurol 2005; 253: 7-13.
Leon-Sarmiento FE, Bayona-Prieto J, Gomez J. Neurophysiology of blepharospasm and multiple system atrophy: clues to pathophysiology. Parkinsonism Relat D 2005; 11 (3): 199-201. DOI:10.1016/jparkreldis.2004.07.011
Rana AQ, Kabir A, Dogu O, Patel A, Khondker S. Prevalence of blepharospasm and apraxia of eye opening in patients with Parkinsonism, cervical dystonia, and essential tremor. Eur Neurol 2012; 68 (5): 318-321. DOI:10.1159/000341621
Scinto LFM, Daffner KR, Dressler D et al. Potential non-invasive neurobiological test for Alzheimer's disease. Science 1994; 266 (5187): 1051-1054. DOI:10.1126/science.7973660
Granholm E, Morris S, Galasko D, Shults C, Rogers E, Vukov B. Tropicamide effects on pupil size and papillary light reflexes in Alzheimer’s and Parkinson’s disease. Int J Psychophysiol 2003; 47(2): 95-115. DOI:10.1016/S0167-8760(02)00122-8
Litvan I, FitzGibbon EJ. Can tropicamide eye drop response differentiate patients with progressive supranuclear palsy and Alzheimer’s disease from healthy control subjects? Neurology 1996; 47 (5): 1324-1326.
Hanyu H, Hirao K, Shimizu S, Kanetaka H, Sakurai H, Iwamoto T. Phenylephrine and pilocarpine eye drop test for dementia with Lewy bodies and Alzheimer’s disease. Neurosci Lett 2007; 414(2): 174-177. DOI:10.1016/j.neulet.2006.12.015
Schmidt C, Herling B, Prieur S, Junghanns S, Schweitzer K, Globas C, Schols L, Antoni S, Ferger D, Reichmann H, Wilhelm H, Berg D, Ziemssen T. Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes. Move Disord 2007: 22 (14): 2123-2126. DOI:10.1002/mds.21721
Kuroda M, Fukura H, Saruki N, Yoshikawa D, Morita T, Goto F. Vecuronium dose requirement and pupillary response in a patient with olivopontocerebellar atrophy (OPCA). Can J of Anaesthesia 1998; 45 (10): 979-984. DOI:10.1136/jnnp.66.1.48
Smith SA, Smith SE. Bilateral Horner’s syndrome: detection and occurrence. J Neurol Neurosurg Psychiatr 1999; 66 (1): 48-51.
Rascol O, Sabatini U, Simonett-Amoreau M, Montrastruc JL, Rascol A, Clanet M Square-wave jerks in Parkinsonism syndromes. J Neurol Neurosurg Psy 1991; 54 (7): 599-602. DOI:10.1136/jnnp.54.7.599
Friedman DI, Jankovic J, McCrary JA. Neuro-ophthalmic findings in progressive supranuclear palsy. J Clin Neuro-ophthalmol 1992; 12 (2): 104-109.
Koop G, Graerf M. Steele-Richardson-Olszewski Syndrome: A report on two cases. Klin Monats Augenheil 2007; 224 (10): 799-803. DOI:10.1055/s-2007-963605
Lepore E. Parkinson’s disease and diplopia. Neuro-opthalmol 2006; 30 (2-3): 37-40. DOI:10.1080/01658100600742838
Shibasaki H, Tsuji S, Kuroiwa Y. Oculomotor abnormalities in Parkinson's disease. Arch Neurol-Chicago 1979; 36 (6): 360-364.
Michell AW, Xu Z, Lewis SJG, Foltynie T, Williams-Gray CH, Robbins TW, Carpenter RHS, Barker RA Saccadic latency distribution in Parkinson’s disease and the effects of L-dopa. Exp Brain Res 2006; 174 (1): 7-18. DOI:10.007/s00221-006-0412-z
Crawford T, Goodrich S, Henderson L, Kennard C. Predictive responses in Parkinson's disease: manual keypresses and saccadic eye movements to regular stimulus events. J Neurol Neurosurg Psych 1989; 52 (9): 1033-1042. DOI:10.1136/jnnp.52.9.1033
Winograd-Gurvich C, Georgiou-Karistianis N, Fitzgerald PB, Millist L, White OB. Self-paced saccades and saccades to oddball targets in Parkinson’s disease. Brain Research 2006 Aug; 1106, 134-141. DOI:10.1016/j.brainres.2006.05.103
Lekwuwa GU, Barnes GR, Collins CJS, Limousin P. Progressive bradykinesia and hypokinesia of ocular pursuit in Parkinsons’s disease. J Neurol Neurosurg Psych 1999, 66 (6), 746-753.DOI:10.1136/jnnp.66.6.746
Corin MS, Elizan TS, Bender MB. Oculomotor function in patients with Parkinson's disease. J Neurol Sci 1971; 15: 251-265.
Mosimann UP, Muri RM, Burn DJ, Felblinger J, O’Brien JT & McKeith IG. Saccadic eye movement changes in Parkinson’s disease dementia and dementia with Lewy bodies. Brain 2005; 128 (6): 1267-1276. DOI:10.1093/brain/awh484
Debruin VM. Lees AJ & Daniel SE. Diffuse Lewy body disease presenting with supranuclear gaze palsy, Parkinsonism and dementia: a case report. Movement Disord 1992; 7 (4): 355-358. DOI:10.1002/mds.870070410
Fearnley JM, Revesz T, Brooks DJ, Frackowiak RS & Lees AJ. Diffuse Lewy body disease presenting with a supranuclear gaze palsy. J Neurol Neurosurg Psych 1991; 54 (2): 159-161. DOI:10.1136/jnnp.542.159
Brett FM, Henson C & Staunton H. Familial diffuse Lewy body disease, eye movements, eye movement abnormalities and distribution of pathology. Arch Neurol 2002; 59 (3): 464-467. DOI:10.1001/archneur.59.3.464
Pinkhardt EH, Jurgens R, Becker W, Valdarno F, Ludolph AC, Kassubek J. Differential diagnostic value of eye movement recording in PSP-Parkinsonism, Richardson’s syndrome, and idiopathic Parkinson’s disease. J Neurol 2008; 155 (12): 1916-1925. DOI:10.1007/S00415-009-0027-y
Kim C, Lee HW, Park MY. Exodeviated ophthalmoplegia in a patient with progressive supranuclear palsy. J Kor Med Sci 2009; 24 (5): 982-984. DOI:10.13346/jkms.2009.24.5.982
Rivaud-Pechoux S, Vidailhet M, Gallouedec G, Litvan I, Gaymard B, Pierrot-Deseilligny C. Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. Neurology 2000; 54 (5): 1029-1032.
Bhidayasiri R, Riley DE, Somers JT, Lerner AJ, Buttner-Ennever JA, Leigh RJ. Pathophysiology of slow vertical saccades in progressive supranuclear palsy. Neurology 2001; 57 (11): 2070-2077.
Rottach KG, Riley DE, DiScenna AO, Zivotofsky AZ, Leigh RJ. Dynamic properties of horizontal and vertical eye movements in Parkinsonism syndromes. Ann Neurol 1996; 39 (3): 368-377. DOI:10.1002/ana.410390314
Das VE, Leigh RJ. Visual-vestibular interaction in progressive supranuclear palsy. Vision Res 2000; 40 (15): 2077-2081. DOI:10.1016/S0042-6989(00)00046-8
Malessa S, Gaymard B, Rivaud S, Cervera P, Hirsch H, Verny M, Duyckaerts C, Agid Y, Pierrot-Deseilligny C. Role of pontine nuclei damage in smooth-pursuit impairment of progressive supranuclear palsy: a clinico-pathological study. Neurology 1994; 44 (4): 716-721.
Garbutt S, Riley DE, Kumar AN, Han Y, Harwood MR, Leigh RJ. Abnormalities of optokinetic nystagmus in progressive supranuclear palsy. J Neurol Neurosurg Psych 2004; 75 (10): 1386-1394. DOI:10.1136/jnnp.2003.027367
Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: A meta analysis. Neurology 1997; 48 (2): 384-393.
Anderson T, Luxon L, Quinn N, Daniel S, Marsden CD, Bronstein A. Oculomotor function in multiple system atrophy: clinical and laboratory features in 30 patients. Move Disord 2008; 23 (7): 977-984. DOI:10.1002/mds.21999
Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological functioning in cortical-basal ganglionic degeneration: Differentiation from Alzheimer’s disease. Neurology 1996; 46 (3): 720-726.
Pierrot-Desilligny C, Rivaud-Pechoux S. Contribution of oculomotor exploitation for the etiological diagnosis of Parkinsonism syndromes. Rev Neurologique. 2003; 159 (5): S75-S81.
Vidailhet M, Rivaud S, Guiderkhouja N, Pillon B, Bonnet AM, Gaymard B, Agid Y, Pierrot-Deseilligny C. Eye-movements in Parkinsonism syndromes. Ann Neurol 1994; 35 (4): 420-426. DOI:10.1002/ana.410350408
Altiparmak UE, Eggenberger E, Coleman A, Condon K. The ratio of square wave jerk rates to blink rate distinguishes progressive supranuclear palsy from Parkinson’s disease. J Neuro-ophthalmol 2006; 26 (4): 257-259. DOI:10.1097/01.wno.0000249326.65227.2e
Pugnetti L, Baglio F, Farina E, Alberoni M, Calbrese E, Gambini A, DeBella E, Garegnani M, Deleonardis L, Neuini R. EEG evidence of posterior cortical disconnection in Parkinson’s disease and related dementias. Int J Neurosci 2010; 120 (2): 88-98. DOI:10.3109/0020745090343646
Tashiro K, Ogata K, Goto Y, Taniwaki T, Okayama A, Kira J, Tobimatsu S. EEG findings in early-stage corticobasal degeneration and progressive supranuclear palsy: A retrospective study and literature review. Clin Neurophys 2006; 117 (10): 2236-2242. DOI:10.1016/jclinph.2006.06.710
Devos D, Tir M, Maurage CA, Waucquier N, Defebvre L, Defoort-Dhellmmes S & Destee A. ERG and anatomical abnormalities suggesting retinopathy in dementia with Lewy bodies. Neurology 2005; 65 (7): 1107-1110. DOI:10.1212/01.wnl.0000178896.44905.33
Langheinrich T, van Elst LT, Lagreze WA, Bach M Lucking CH, Greenlee MW. Visual contrast response functions in Parkinson’s disease: evidence from electroretinogram, visually evoked potentials and psychophysics. Clin Neurophysiol 2000; 111 (1): 66-74. DOI:10.1016/S1388-2457(99)00223.0
Sartucci F, Orlandi G, Bonuccelli U, Borghetti D, Murri L, Orsini C, Domenici L, Porciatti V. Chromatic pattern-reversal electroretinogram (ChPERG) are spared in multiple system atrophy compared with Parkinson’s disease. Neurol Sci 2006; 26 (6): 395-401. DOI:10.1007/s10072-006-0522-1
Buttner T, Kuhn W, Muller T, Heinze T, Puhl C, Przuntek H. Chromatic and achromatic visual evoked potentials in Parkinson’s disease. Electroen Clin Neurol 1996; 100 (5): 443-447.
Masanaka T, Hisao T, Keita K, Yasunobu K, Hiroo Y, Bungo O. Multi-modal evoked potentials in corticobasal degeneration, progressive supranuclear palsy, and Alzheimer’s disease. In: Unveiling the mystery of the brain: Neurophys Inv Brain Func: Int Cong Ser 2005; 1278: 145-148. DOI:10.1016/j.ics.2004.11.069
Delalande I, Hache JC, Forzy G, Bughin M, Benhadjali J, Destee A. Do visual evoked potentials and spatial-temporal contrast sensitivity help to distinguish idiopathic Parkinson’s disease and multiple system atrophy. Move Disord 1998; 13 (5): 446-452. DOI:10.1002/mds.870130312
Pierrot-Deseilligny C, Turell E, Penet C, Lebrigand D, Pillon B, Chain F, Agid Y Increased wave P300 latency in progressive supranuclear palsy. J Neurol Neurosurg Psych 1989; 52 (5): 656-658. DOI:10.1136/jnnp.52.5.656
Johnson R, Litvan I, Grafman J. Progressive supranuclear palsy: altered sensory processing leads to degraded cognition. Neurology 1991; 41 (8): 1257-1262.
Koga Y, Nagata K, Hirata K. Hypothesis on the P300 generators based on visual P300 results in neurological disorders. Brain Topog Tod: Int Cong Series 1997; 1147: 354-357.
Wang LH Kuroiwa Y, Kamitani T, Li M, Takahashi T, Suzuki Y, Shimamura M, Hasegawa O. Visual event-related potentials in progressive supranuclear palsy, corticobasal degeneration, striatonigral degeneration and Parkinsons’s disease. J Neurol 2000; 247 (5): 356-363. DOI:10.1007/s004150050602
Kamitani T, Kuroiwa T, Wang LH, Li M, Suzuki Y, Takahashi T, Ikegami T, Matsubara S. Visual event-related potential changes in two subtypes of multiple system atrophy, MSA-C and MSA-P. J Neurol 2002; 249 (8): 975-982. DOI:10.1007/S00415-002-0764-7
Kamitani T, Kuroiwa Y. Visual event-related potential changes in multiple system atrophy: delayed N2 latency in selective attention to a color task. Park Dis Rel Disord 2009; 15 (1): 36-40. DOI:10.1016/jparkreldis.2008.02.009
Mori E, Shimomura T, Fujimori M, Horono N, Imamura T, Hashimoto M, Tanimukai S, Kaui H, Hanihara T. Visuoperceptual impairment in dementia with Lewy bodies. Arch Neurol 2000; 57 (4): 489-493. DOI:10.001/archneur.57.4.489
Metzler-Baddeley C, Baddeley RJ, Lovell PG, Laffan A, Jones RW. Visual impairment in dementia with Lewy bodies and posterior cortical atrophy. Neuropsych 2010; 24 (1): 35-48. DOI:10.1037/a0016834
Mondon K, Gochard A, Margue A, Armand A, Beauchamp D, Pruncer C, Jacobi D, de Toffol B, Autret A, Camus V, Hommet C. Visual recognition memory differentiates dementia with Lewy bodies and Parkinson’s disease dementia. J Neurol Neurosurg Psych 2007; 78 (7): 738-741. DOI:10.1136/jnnp.104257
Levin BE, Llabre MM, Reisman S, Weiner WJ, Sanchez-Ramos J, Singer C, Brwon MC. Visuospatial impairments in Parkinson's disease. Neurology 1991; 41 (3): 365-369.
Davidsdottir S, Cronin-Golomb A, Lee A. Visual and spatial symptoms in Parkinsons’s disease. Vision Res 2005; 45 (10): 1285-1296. DOI:10.1016/j.visres.2004.11.006
Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble RJ. Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer’s disease. J Neurol Neurosurg Psych 2001; 70 (4): 483-488. DOI:10.1136/jnnp.70.4.483
Trick GL, Kaskie B, Steinman SB. Visual impairment in Parkinson's disease: Deficits in orientation and motion discrimination. Optometry Vis Sci 1994; 71 (4): 242-245. DOI:10.1097/00006324-199404000-00002
Lang PJ. A bio-informational theory of emotional imagery. Psychophysiology 1979; 16 (6): 495-512. DOI:10.1111/j.1469-8986.1979.tb.01511.x
Sprengelmeyer R, Young AW, Mahn K, Schroeder U, Woitalla D, Buttner T, Kuhn W, Przuntek H. Facial expression recognition in people with medicated and unmedicated Parkinson’s disease. Neuropsychology 2003; 41 (8): 1047-1057. DOI:10.1016/S0028-3932(02)00295-6
Jacobs DH, Shuren J, Bowers D & Heilman KM. Emotional facial imagery, perception and expression in Parkinson's disease. Neurology 1995; 45 (9): 1696-1702.
Podoll K, Schwarz M, Noth J. Language problems in progressive supranuclear palsy. Brain 1991; 114 (3): 1457-1472. DOI:10.1093/brain/114.3.1457
Sachin S, Shukla G, Goyal V, Singh S, Aggarwal V, Guresh-Kumar, Behari M. Clinical speech impairment in Parkinson’s disease, progressive supranuclear palsy, and multiple system atrophy. Neurology India 2008; 56 (2): 122-126.
Jellinger KA, Grazer A, Petrovic K, Ropele S, Alpi G, Kapeller P, Strobel T, Schmidt R. Four-repeat tauopathy clinically presenting as posterior cortical atrophy: atypical corticobasal degeneration? Acta Neuropathol 2011; 121 (2): 267-277. DOI:10.1007/s00401-010-0712-z
Bak TH, Caine D, Nearn VC, Hodges JR. Visuospatial functions in atypical Parkinsonism syndromes. J Neurol Neurosur PS 2006: 77 (4): 454-456. DOI:10.1136/jnnp.2005.068239
Graham NL, Bak T, Patterson K, Hodges JR. Language function and dysfunction in corticobasal degeneration. Neurology 2003: 61 (4): 493-499.
Tang-Wai DF, Josephs KA, Boeve BF, Dickson DW, Parisi JE, Petersen RC. Pathologically confirmed corticobasal degeneration presenting with visuospatial dysfunction. Neurology 2003; 61 (8): 1134-1135. DOI:10.1212/01.WNL.0000086814.35352.B3
Chapman FM, Dickinson J, McKeith I & Ballard C. Association among visual associations, visual acuity, and specific eye pathologies in Alzheimer’s disease: Treatment implications. Am J Psych 1999; 156 (12): 1983-1985.
Archibald NK, Clarke MP, Mosimann UP, Burn, D.J. Visual symptoms in Parkinson’s disease and Parkinson’s disease dementia. Movement Disord 2011; 26 (13): 2387-2395. DOI:10.1002/mds.23891
Ebersbach G. Hallucinations and psychosis in Parkinson’s disease: consequences for diagnosis and management. Nervenheilkundt 2008; 27: 709.
Hely MA, Reid WG, Halliday GM, McRitchie DA, Leicester J, Joffe R, Brooks W, Broe GA, Morris JGL. Diffuse Lewy body disease: clinical features in nine cases without coexistant Alzheimer’s disease. J Neurol Neurosurg Psych 1996; 60 (5): 531-538. DOI:10.1136/jnnp.60.5.531
Diederich NJ, Goetz CG & Stebbins GT. Repeated visual hallucinations in Parkinsons’s disease as disturbed external/internal perceptions: Focused review and a new integrative model. Movement Disord 2005; 20 (2): 130-140. DOI:10.1002/mds.20308
Oertel WH, Depboylu C, Krenzer M, Vadasz D, Ries V, Sixel-Doring F, Mayer G REM sleep behavior disorder as a prodromal stage of alpha-synucleinopathies: Symptoms, epidemiology, pathophysiology, diagnosis and therapy. Nervenarzt 2014; 85 (1), 19-25. DOI:10.1007/s00115-013-3891-8
Turner RS. Idiopathic rapid eye movement sleep behavior disorder is a harbinger of dementia with Lewy bodies. J Geriatr Psych Neur 2002; 15 (4): 195-199.
Cooper AD, Josephs KA. Photophobia, visual hallucinations, and REM sleep behavior disorder in progressive supranuclear palsy and corticobasal degeneration: A prospective study. Parkinsonism Relat D 2009, 15 (1): 59-61. DOI:10.1016/j.parkeldis.2008.01.011
Postuma RB, Gagnon JF, Pelletier A, Montplaisir J. Prodromal autonomic symptoms and signs in Parkinson’s disease and dementia with Lewy bodies. Movement Disord 2013; 28 (5): 597-604. DOI:10.1002/mds.25445
Bares M, Brazdil M, Kanovsky P, Jurak P, Daniel P, Kukleta M, Rektor I. The effect of apomorphine administration on smooth pursuit ocular movements in early Parkinson’s disease. Parkinson Rel Disord 2003; 9 (3), 139-144. DOI:10.1016/S1353-8020(02)00015-9
Sato E, Onitsuka T, Ninomiya H, Nakamura I, Kanba S. Prism adaptation and perceptual skill learning deficits in early-stage Parkinson’s disease. Neuropsychobiology 2014; 70 (3): 165-172. DOI:10.1159/000365485
Goldman JG, Postuma R. Premotor and non-motor features of Parkinson’s disease. Curr Opin Neurol 2014; 27(4): 434-441. DOI:10.1097?WCO.0000000000000112
Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to differentiate Parkinson’s disease from atypical Parkinsonism. J Neurol Neurosurg Psych 2008; 79 (6): 652-655. DOI:10.1136/jnnp.2007.124677
Averbuch-Heller L, Paulson GW, Daroff RB, Leigh RJ. Whipple’s disease mimicking progressive supranuclear palsy, the diagnostic value of eye movement recording. J Neurol Neurosurg Psych 1999; 66 (4): 532-535. DOI:10.1136/jnnp.66.4.532
Kaufer DI. Pharmacologic treatment expectations in the management of dementia with Lewy bodies. Dem Geriatr Cog Dis 2004; 17 (1): 32-39. DOI:10.1159/000074680
Antoniades CA, Bak TH, Carpenter RHS, Hodges JR, Barker RA. Diagnostic potential of saccadometry in progressive supranuclear palsy. Biomark Med 2007; 1 (4): 487-490. DOI:10.2217/17520363.1.4.487
Kumbier E, Kornhuber M. Delusional parasitosis in multiple system atrophy. Nervenarzt 2002; 73 (4): 380-383. DOI:10.1007/s00115-002-1273-8
Pinkhardt EH, Kassubek J, Sussmuth S, Ludolph AC, Becker W, Jurgens R. Comparison of smooth pursuit eye movement deficits in multiple system atrophy and Parkinson’s disease. Journal of Neurology 2009; 256 (9): 1438-1446. DOI:10.1007/s00415-009-5131-5
Ekker MS, Janssen S, Nonnekes J, Bloem BR, de Vries NM. Neurorehabilitation for Parkinson’s disease: Future perspectives for behavioral adaptation. Park Rel Disord 2016; 22 (1): S73-S77. DOI:10.1016/j.parkreldis.2015.08.031
Rey GJ, Tomer R, Levin BE, Sanchez-Ramos J, Bowen B, Bruce JH. Psychiatric symptoms, atypical dementia, and left visual-field inattention in corticobasal ganglionic degeneration. Movement Disord 1995; 10 (1): 106-110. DOI:10.1002/mds.870100117
Formaglio M, Krolak-Salmon P, Tilikete C, Bernard M, Croisile B, Vighetto A. Homonymous hemianopia and posterior cortical atrophy. Rev Neurol 2009: 165 (3): 256-262. DOI:10.1015/j.neurol.2008.10.010
Di Fabio RP, Zampieri C, Tuite P. Gaze control and foot kinematics during stair climbing: Characteristics leading to fall risk in progressive supranuclear palsy. Phys Therapy 2008; 88 (2), 240-250. DOI:10.2522/ptj.20070159
Hill E, Stuart S, Lord S, Del Din S, Rochester L. Vision, visuo-cognition and postural control in Parkinson’s disease: An associative pilot study. Gait and Posture 2016 Jul; 48: 74-76. DOI:10.1016/j.gaitpost.2016.04.024
Lin TP, Rigby H, Adler JS, Hentz JG, Balcer LJ, Galetta SL, Devick S, Cronin R, Adler CH. Abnormal visual contrast acuity in Parkinson’s disease. J Park Dis 2015; 5 (1): 125-130. DOI:10.3233/JPD-140470
Alvarez FJ. Parkinson’s disease, antiparkinson medicines, and driving. Expert Rev Neurotherapeut 2016; 16 (9): 1023-1032. DOI:10.1080/14737175.2016.1218278
DOI: http://dx.doi.org/10.18103/imr.v4i3.679
Refbacks
- There are currently no refbacks.